were the first to draw attention to this in one of their patients, and confirmation has come from Hoyumpa and Connell (1973) and Goldstein et al. (1973) . The latter authors, in an investigation of the aetiology of 21 consecutive cases of active chronic hepatitis in their unit in 12 months, found no fewer than 14 cases which they considered to be drug induced. Of these, nine were associated with ingestion of oxyphenisatin and five methyldopa. In an analysis of the histological features they found that in active chronic hepatitis due to methyldopa there was milder liver cell necrosis and a lower incidence of cirrhosis than in active chronic hepatitis due to oxyphenisatin and active chronic hepatitis of unknown origin. They also commented on the better initial improvement in patients with chronic hepatitis who were able to stop taking their drug as compared with those in the "unknown origin" group. As with the haemolytic anaemia due to methyldopa it seems likely that the development of active chronic hepatitis has an immunological basis. Unfortunately autoantibody studies were not always reported in earlier papers and, in particular, the incidence of smooth muscle antibody is not known.
While proof of the aetiological role of methyldopa may be obtained by a rechallenge with the drug we feel that this is a highly dangerous procedure which may be followed by fatal hepatic necrosis. Some of the deaths from hepatic necrosis reported in the literature have resulted from accidental or deliberate rechallenge with the drug (Rehman et al., 1973; Hoyumpa and Connell, 1973) . Though the first episode of liver damage may be delayed for several weeks after the initial treatment with methyldopa it seems clear that readministration of the drug may elicit a prompt and dramatic exacerbation of the liver injury.
In view of the high incidence of mild abnormalities in liver function after starting treatment with methyldopa we feel that there is little point in carrying out routine tests during the first few weeks of treatment. Clearly routine testing will not screen out those patients who may progress to clinical liver damage. Our experience, however, of a patient with undiagnosed cirrhosis who died from superimposed liver damage from methyldopa indicates the need for caution. It seems prudent, therefore, to check the results of routine liver function tests before starting treatment in all patients, and it is clearly dangerous to give methyldopa to patients with overt liver disease. An awareness of the possibility of methyldopa hepatotoxicity is probably the most important point and, above all, there must be a strict avoidance of the temptation to perform a clinical rechallenge, an exercise which may result in disaster. A shortened version of this paper was presented at the spring meeting of the British Society of Gastroenterology, 1974. Introduction Though vascular thromboses are a known complication of essential thromrbocythaemia it is usually major vessels which are affected (Gunz, 1960) and there have been surprisingly few reports on the importance of this condition as a cause of peripheral vascular disease.
The six patients described here were all diagnosed as having essential thrombocythaemia while awaiting surgical intervention for gangrene of one or more toes. A causal relationship between the platelet abnormalities and the vascular lesions is afforded by the observations that striking relief from pain coincided with improved platelet function after the administration of aspirin. Moreover, recurrence of pain was temporally associated with recurrence of the abnormal platelet function.
Treatment with 34P corrected the platelet counts of all six patients, who remained well and pain free. Platelet function also became normal.
Patients and Methods
The patients, all men, were investigated and treated during August 1972 A 59-year-old man was admitted to hospital in June 1973 for amputation of a pregangrenous fourth left toe. For two months he had complained of severe pain of the affected toe. and this had become cyanosed and ulcerated in the two weeks before admission. Arteriography had shown nothing of note and on clinical examination all peripheral pulses were palpable. The patient had been well until 1971, when he had two separate, radiologically confirmed, deep vein thromboses whioh had been treated with anticoagulants. In 1972 he had a myocardial infa,rotion and since then had been taking oral anticoagulants.
While awaiting amputation numerous large platelets were noted on the peripheral blood film and the platelet count was found to be raised (825,000/mm3). Further investigation-, were performed (tables I and II) and other causes of peripheral vascular disease and secondary thrombocythaemia were excluded. It was concluded that the diagnosis was essential thrombocythaemia and after discontinuing the anticoagulants the patient was given aspirin and 4 mCi cf 32p. The clinical response to aspirin was particularly dramatic and four hours after taking the first 600 mg he was pain free and able to walk around the ward. During the next few days the colour of the affected toe improved and amputation was deemed unnecessary. During the next few weeks the platelet count gradually fell to normal, aspirin was withdrawn, and two weeks later the platelet function was found to be normal. No further treatment was given and the patient remained symptom free without evidence of peripheral vascular disease.
PLATELET FUNCTION Platelet-rich plasma was prepared from venous blood collected into siliconized tubes using 1/10 volume (3-8 % w/v) sodium citrate as anticoagulant. Specimens were centrifuged at 600 g for five minutes. The platelet-rich plasma was diluted with the patient's own platelet-poor plasma to give a final concentration of 250,000/mm3. Plasma samples were kept at room temperature in siliconized tubes and tested 60 minutes after venesection. Aggregation studies were performed using an E.E.L. aggregometer and a Telsec flat-bed recorder.
The aggregating reagents used were adenosine diphosphate (ADP) 2 5 )ug/ml) and bovine tendo Achillis collagen (Sigma Chemical Co.). The terms used to describe the platelet aggregation (table II) In all six patients platelet counts fell to normal levels within a few weeks of the intravenous administration of 32P. Plate- 
patients with peripheral vascular disease, and thrombocytosis does not appear to be the usual response to this disorder.
It is of interest that none of our patients had any evidence of a bleeding tendency, which is a frequent complication of myeloproliferative thrombocythaemia (Hardisty and Wolff, 1955; Gunz, 1960; Fountain and Losowsky, 1962) . In this context only one patient had a platelet count greater than 1 x 106/mm'. Most of the previously described patients with haemorrhagic thrombocythaemia had platelet counts well in excess of 1 x 106/mm3 (Ozer et al., 1960; Fountain and Losowsky, 1962) and it may be that patients with essential thrombocythaemia and a relatively low platelet count are 2 3 4 more likely to develop vascular thromboses than abnormal haemorrh,age.
(a) before aspirin and Thrombotic episodes are well known complications of essential thrombocythaemia but most workers have laid emphasis on the involvement of the larger vessels, particularly thrombosis of the splenic vein, and there have been only sporadic reports of peripheral gangrene as a presenting feature of this condition. Moreover, though attempts have been made to determine the cause of the abnormal bleeding in essential thrombocythaemia there have been few reports of abnormal platelet function in the thrombotic variant of this disorder.
The platelets of all our six patients showed marked enhancement of aggregation to ADP and collagen. Of particular interest was the spontaneous platelet aggregation which was observed in platelet-rich plasma from four of the five patients in whom this investigation was undertaken. This abnormality has been previously described in a patient with idiopathic thrombosis and recurrent painful toes and fingers (Vreeken and Van Aken, 1971) . Examination of the data in that report suggests that the patient had essential thrombocythaemia, and again the initial platelet count was less than 1 10J/mm:. normal platelets in the affected patient's plasma and then repeating the investigation. Platelet aggregation was not observed. Conversely the spontaneous aggregation could be reproduced by resuspending the patient's platelets in normal count was normal, plasma. as no evidence of All of our patients complained of severe pain affecting one or more toes. The administration of aspirin 600-900 mg was followed by rapid and striking relief of pain. This response was reported by Bierme et al. (1972) and we believe that it may be a useful diagnostic test of thrombocythaemic-induced gangrene. ,ociation with carCoincident with the positive clinical response the ingestion It is also a recogof aspirin was associated in all six patients with marked imdisorders, notably pairment of collagen-induced platelet aggregation. This effect chronic myeloid has been described by a number of workers (Mills, 1972) and Registry, 1972; Brunner et al., 1972; Lowrie et al., 1973) suggests a higher mortality from these causes than in the normal population.
To determine the accuracy of this observation the mortality due to acute coronary and cerebral arterial thrombosis was determined in a consecutive series of 325 patients who received cadaveric renal transplants during a six-year period. (Sheil et al., 1972 (Sheil et al., , 1973 Statistics (O'Neill, 1971) were used to derive the expected mortality from these causes in the number of person years at risk in the transplant population. Since the probability of death from either of these causes is small statistical analysis was based on a Poisson approximation.

Results
Of the 100 deaths in this transplant population nine were certainly and two possibly due to acute coronary occlusion, and three resulted from cerebral thrombosis (table I) . Necropsy confirmation was obtained in all three with cerebral thrombosis and in seven of the patients with coronary thrombosis. In the two other certain cases myocardial infarction was proven by serial electrocardiography and serum enzyme determinations after their admission to hospital with a clinical history suggestive of this diagnosis. Death was possibly due to coronary artery occlusion in two patients who died suddenly at home when in apparently good health (one had had severe atherosclerosis).
Seven deaths were due to cerebral haemorrhage. Three of these occurred in patients on anticoagulant therapy, and one was due to a ruptured cerebral aneurysm. In this study these seven deaths were excluded from further consideration.
Occlusive vascular mortality was greatest in the early posttransplantation period, and five deaths occurred in the first month and three others in the next two months after operation. Five of the nine patients dying from proven coronary artery occlusion had had ischaemic heart disease before transplantation. Graft function at the time of acute arterial occlusion was good in all but two patients (cases 9 and 14). In one further patient (case 4) poor graft function at the time of his death was due to prolonged hypotension resulting from his myocardial infarction.
The calculated expected mortality in this transplant population was 0-36 death from myocardial infarction and 0-01 from cerebral thrombosis. The observed mortalities-nine and three deaths-were respectively 25 times and 300 times greater, both highly significant increases.
When the renal allograft recipients were grouped according to their original renal disease those with essential hypertension had the highest overall death rate (table II) . This was due to a mortality from occlusive arterial disease of 26%, which was significantly higher than that of the patients in any of the other diagnostic categories except those with polycystic renal disease.
